The central biobank and virtual biobank of BiOMarKaPD: a resource for studies on neurodegenerative diseases

Babette L. R. Reijs; Charlotte E. Teunissen; Nikolai Goncharenko; Fay Betsou; Kaj Blennow; Ines Baldeiras; Frederic Brosseron; Enrica Cavedo; Tormod Fladby; Lutz Froelich; Tomasz Gabryelewicz; Hakan Gurvit; Elisabeth Kapaki; Peter Koson; Luka Kulic; Sylvain Lehmann; Piotr Lewczuk; Alberto Lleo; Walter Maetzler; Alexandre de Mendonca; Anne-Marie Miller; Jose L. Molinuevo; Brit Mollenhauer; Lucilla Parnetti; Uros Rot; Anja Schneider; Anja Hviid Simonsen; Fabrizio Tagliavini; Magda Tsolaki; Marcel M. Verbeek; Frans R. J. Verhey; Marzena Zboch; Bengt Winblad; Philip Scheltens; Henrik Zetterberg; Pieter Jelle Visser

doi:10.3389/fneur.2015.00216

The central biobank and virtual biobank of BiOMarKaPD: a resource for studies on neurodegenerative diseases

Babette L. R. Reijs^*, Charlotte E. Teunissen, Nikolai Goncharenko, Fay Betsou, Kaj Blennow, Ines Baldeiras, Frederic Brosseron, Enrica Cavedo, Tormod Fladby, Lutz Froelich, Tomasz Gabryelewicz, Hakan Gurvit, Elisabeth Kapaki, Peter Koson, Luka Kulic, Sylvain Lehmann, Piotr Lewczuk, Alberto Lleo, Walter Maetzler, Alexandre de MendoncaAnne-Marie Miller, Jose L. Molinuevo, Brit Mollenhauer, Lucilla Parnetti, Uros Rot, Anja Schneider, Anja Hviid Simonsen, Fabrizio Tagliavini, Magda Tsolaki, Marcel M. Verbeek, Frans R. J. Verhey, Marzena Zboch, Bengt Winblad, Philip Scheltens, Henrik Zetterberg, Pieter Jelle Visser

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Biobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's disease (BIOMARKAPD) is a European multi-center study, funded by the EU Joint Programme-Neurodegenerative Disease Research, which aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer's disease (AD) and Parkinson's disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized pre-analytical procedures and stored at Integrated BioBank of Luxembourg. The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia, multiple system atrophy, progressive supranuclear palsy, PD, PD with dementia, and dementia with Lewy bodies. The virtual biobank contains information on over 8,600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank.

Original language	English
Article number	216
Journal	Frontiers in Neurology
Volume	6
DOIs	https://doi.org/10.3389/fneur.2015.00216
Publication status	Published - 15 Oct 2015

Keywords

biobank
cerebrospinal fluid
dementia
Alzheimer's disease
Parkinson's disease
neurodegenerative disorders
body fluids

Access to Document

10.3389/fneur.2015.00216Licence: CC BY

Cite this

Reijs, B. L. R., Teunissen, C. E., Goncharenko, N., Betsou, F., Blennow, K., Baldeiras, I., Brosseron, F., Cavedo, E., Fladby, T., Froelich, L., Gabryelewicz, T., Gurvit, H., Kapaki, E., Koson, P., Kulic, L., Lehmann, S., Lewczuk, P., Lleo, A., Maetzler, W., ... Visser, P. J. (2015). The central biobank and virtual biobank of BiOMarKaPD: a resource for studies on neurodegenerative diseases. Frontiers in Neurology, 6, Article 216. https://doi.org/10.3389/fneur.2015.00216

@article{a2e740d114fd42fc80c17b8d0c5e4361,

title = "The central biobank and virtual biobank of BiOMarKaPD: a resource for studies on neurodegenerative diseases",

abstract = "Biobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's disease (BIOMARKAPD) is a European multi-center study, funded by the EU Joint Programme-Neurodegenerative Disease Research, which aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer's disease (AD) and Parkinson's disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized pre-analytical procedures and stored at Integrated BioBank of Luxembourg. The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia, multiple system atrophy, progressive supranuclear palsy, PD, PD with dementia, and dementia with Lewy bodies. The virtual biobank contains information on over 8,600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank.",

keywords = "biobank, cerebrospinal fluid, dementia, Alzheimer's disease, Parkinson's disease, neurodegenerative disorders, body fluids",

author = "Reijs, {Babette L. R.} and Teunissen, {Charlotte E.} and Nikolai Goncharenko and Fay Betsou and Kaj Blennow and Ines Baldeiras and Frederic Brosseron and Enrica Cavedo and Tormod Fladby and Lutz Froelich and Tomasz Gabryelewicz and Hakan Gurvit and Elisabeth Kapaki and Peter Koson and Luka Kulic and Sylvain Lehmann and Piotr Lewczuk and Alberto Lleo and Walter Maetzler and {de Mendonca}, Alexandre and Anne-Marie Miller and Molinuevo, {Jose L.} and Brit Mollenhauer and Lucilla Parnetti and Uros Rot and Anja Schneider and Simonsen, {Anja Hviid} and Fabrizio Tagliavini and Magda Tsolaki and Verbeek, {Marcel M.} and Verhey, {Frans R. J.} and Marzena Zboch and Bengt Winblad and Philip Scheltens and Henrik Zetterberg and Visser, {Pieter Jelle}",

year = "2015",

month = oct,

day = "15",

doi = "10.3389/fneur.2015.00216",

language = "English",

volume = "6",

journal = "Frontiers in Neurology",

issn = "1664-2295",

publisher = "Frontiers Media S.A.",

}

Reijs, BLR, Teunissen, CE, Goncharenko, N, Betsou, F, Blennow, K, Baldeiras, I, Brosseron, F, Cavedo, E, Fladby, T, Froelich, L, Gabryelewicz, T, Gurvit, H, Kapaki, E, Koson, P, Kulic, L, Lehmann, S, Lewczuk, P, Lleo, A, Maetzler, W, de Mendonca, A, Miller, A-M, Molinuevo, JL, Mollenhauer, B, Parnetti, L, Rot, U, Schneider, A, Simonsen, AH, Tagliavini, F, Tsolaki, M, Verbeek, MM, Verhey, FRJ, Zboch, M, Winblad, B, Scheltens, P, Zetterberg, H & Visser, PJ 2015, 'The central biobank and virtual biobank of BiOMarKaPD: a resource for studies on neurodegenerative diseases', Frontiers in Neurology, vol. 6, 216. https://doi.org/10.3389/fneur.2015.00216

TY - JOUR

T1 - The central biobank and virtual biobank of BiOMarKaPD: a resource for studies on neurodegenerative diseases

AU - Reijs, Babette L. R.

AU - Teunissen, Charlotte E.

AU - Goncharenko, Nikolai

AU - Betsou, Fay

AU - Blennow, Kaj

AU - Baldeiras, Ines

AU - Brosseron, Frederic

AU - Cavedo, Enrica

AU - Fladby, Tormod

AU - Froelich, Lutz

AU - Gabryelewicz, Tomasz

AU - Gurvit, Hakan

AU - Kapaki, Elisabeth

AU - Koson, Peter

AU - Kulic, Luka

AU - Lehmann, Sylvain

AU - Lewczuk, Piotr

AU - Lleo, Alberto

AU - Maetzler, Walter

AU - de Mendonca, Alexandre

AU - Miller, Anne-Marie

AU - Molinuevo, Jose L.

AU - Mollenhauer, Brit

AU - Parnetti, Lucilla

AU - Rot, Uros

AU - Schneider, Anja

AU - Simonsen, Anja Hviid

AU - Tagliavini, Fabrizio

AU - Tsolaki, Magda

AU - Verbeek, Marcel M.

AU - Verhey, Frans R. J.

AU - Zboch, Marzena

AU - Winblad, Bengt

AU - Scheltens, Philip

AU - Zetterberg, Henrik

AU - Visser, Pieter Jelle

PY - 2015/10/15

Y1 - 2015/10/15

N2 - Biobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's disease (BIOMARKAPD) is a European multi-center study, funded by the EU Joint Programme-Neurodegenerative Disease Research, which aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer's disease (AD) and Parkinson's disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized pre-analytical procedures and stored at Integrated BioBank of Luxembourg. The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia, multiple system atrophy, progressive supranuclear palsy, PD, PD with dementia, and dementia with Lewy bodies. The virtual biobank contains information on over 8,600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank.

AB - Biobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's disease (BIOMARKAPD) is a European multi-center study, funded by the EU Joint Programme-Neurodegenerative Disease Research, which aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer's disease (AD) and Parkinson's disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized pre-analytical procedures and stored at Integrated BioBank of Luxembourg. The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia, multiple system atrophy, progressive supranuclear palsy, PD, PD with dementia, and dementia with Lewy bodies. The virtual biobank contains information on over 8,600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank.

KW - biobank

KW - cerebrospinal fluid

KW - dementia

KW - Alzheimer's disease

KW - Parkinson's disease

KW - neurodegenerative disorders

KW - body fluids

U2 - 10.3389/fneur.2015.00216

DO - 10.3389/fneur.2015.00216

M3 - Article

C2 - 26528237

SN - 1664-2295

VL - 6

JO - Frontiers in Neurology

JF - Frontiers in Neurology

M1 - 216

ER -